# A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia

> **NCT01606436** · PHASE1 · COMPLETED · sponsor: **Denovo Biopharma LLC** · enrollment: 86 (actual)

## Conditions studied

- Schizophrenic Disorders

## Interventions

- **DRUG:** LY2140023
- **DRUG:** Placebo
- **DRUG:** Moxifloxacin

## Key facts

- **NCT ID:** NCT01606436
- **Lead sponsor:** Denovo Biopharma LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2012-08
- **Final completion:** 2012-09
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2023-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01606436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01606436, "A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01606436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*